Clinical Trial Update: Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and efficacy of an anti-IL6 receptor nanobody in rheumatoid arthritis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Anti-Interleukin 6-receptor (IL6R) nanobody (IL6R nanobody)

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED